![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C19H23NO2 |
Molar mass | 297.398 g·mol−1 |
3D model ( JSmol) | |
| |
|
Minamestane ( INN (former developmental code name FCE-24,928) is a steroidal aromatase inhibitor which was under development by Farmitalia-Carlo Erba as an antineoplastic agent in the mid-1990s but was never marketed. [1] [2] [3]
Unlike other steroidal aromatase inhibitors such as formestane and exemestane, minamestane does not have androgenic properties. [2]
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C19H23NO2 |
Molar mass | 297.398 g·mol−1 |
3D model ( JSmol) | |
| |
|
Minamestane ( INN (former developmental code name FCE-24,928) is a steroidal aromatase inhibitor which was under development by Farmitalia-Carlo Erba as an antineoplastic agent in the mid-1990s but was never marketed. [1] [2] [3]
Unlike other steroidal aromatase inhibitors such as formestane and exemestane, minamestane does not have androgenic properties. [2]